Update in treatment options for psoriatic arthritis.

about

Drug persistence, effectiveness and safety assessment of anti-TNF therapies in psoriatic arthritis.Orthopaedic interventions in patients with psoriatic arthritis: a descriptive report from the SPAR cohort.

P2860

Q37826195-53F0C87A-F3B6-4D48-A9EC-F87F98FEC3EB Q39367830-7CD44D29-2AF7-41FF-ACD5-B66CFF23BDC4

P2860

Update in treatment options for psoriatic arthritis.

Item

http://www.wikidata.org/entity/Q43061552

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Update in treatment options for psoriatic arthritis.

@en

Update in treatment options for psoriatic arthritis.

@nl

type

Item

label

Update in treatment options for psoriatic arthritis.

@en

Update in treatment options for psoriatic arthritis.

@nl

prefLabel

Update in treatment options for psoriatic arthritis.

@en

Update in treatment options for psoriatic arthritis.

@nl

P1476

Update in treatment options for psoriatic arthritis.

@en

P2093

Kurt de Vlam

http://www.w3.org/2001/XMLSchema#string

Rik J Lories

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up.

Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins.

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.

P304

779-788

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ECI.09.49

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20477696

http://www.w3.org/2001/XMLSchema#string

Update in treatment options for psoriatic arthritis.

about

P2860

P2860

Update in treatment options for psoriatic arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698